Cardiac gene editing holds promising potential in revolutionizing the landscape of cardiovascular medicine. This innovative field involves precisely modifying the genetic code within cardiac cells to address and rectify underlying genetic factors contributing to heart diseases. By leveraging advanced molecular tools such as CRISPR-Cas9, researchers aim to target specific genes associated with cardiac conditions, paving the way for personalized therapeutic interventions. The ability to edit genes directly in cardiac tissue opens new avenues for treating congenital heart disorders, genetic predispositions, and other cardiovascular ailments. While still in the early stages of development, cardiac gene editing represents a cutting-edge approach that holds great promise for advancing our understanding of cardiac health and fostering breakthroughs in tailored treatments for individuals with various cardiovascular conditions.
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain
Title : Innovative mechanisms, consequences and therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Comprehensive surgical revascularization for rapidly worsening ischemic heart failure
Deepak Puri, Max Healthcare, India